Teacher Retirement System of Texas Decreases Holdings in Omnicell, Inc. (NASDAQ:OMCL)

Teacher Retirement System of Texas trimmed its holdings in Omnicell, Inc. (NASDAQ:OMCL - Free Report) by 47.9% in the 1st quarter, according to its most recent disclosure with the SEC. The firm owned 13,901 shares of the company's stock after selling 12,781 shares during the period. Teacher Retirement System of Texas' holdings in Omnicell were worth $486,000 at the end of the most recent quarter.

Several other hedge funds also recently added to or reduced their stakes in OMCL. Vanguard Group Inc. boosted its position in shares of Omnicell by 0.5% during the fourth quarter. Vanguard Group Inc. now owns 5,562,165 shares of the company's stock worth $247,628,000 after buying an additional 28,573 shares during the period. Dimensional Fund Advisors LP raised its stake in shares of Omnicell by 31.6% in the fourth quarter. Dimensional Fund Advisors LP now owns 1,642,626 shares of the company's stock valued at $73,127,000 after acquiring an additional 394,820 shares in the last quarter. Lazard Asset Management LLC raised its stake in shares of Omnicell by 81.6% in the fourth quarter. Lazard Asset Management LLC now owns 1,641,817 shares of the company's stock valued at $73,093,000 after acquiring an additional 737,536 shares in the last quarter. ArrowMark Colorado Holdings LLC raised its stake in shares of Omnicell by 4.9% in the fourth quarter. ArrowMark Colorado Holdings LLC now owns 1,196,990 shares of the company's stock valued at $53,290,000 after acquiring an additional 56,117 shares in the last quarter. Finally, Toronto Dominion Bank acquired a new stake in shares of Omnicell in the fourth quarter valued at $30,637,000. 97.70% of the stock is currently owned by hedge funds and other institutional investors.

Omnicell Stock Performance

OMCL traded down $1.09 during trading on Friday, reaching $26.88. The company's stock had a trading volume of 621,402 shares, compared to its average volume of 563,445. Omnicell, Inc. has a 52-week low of $22.66 and a 52-week high of $55.75. The company's fifty day moving average price is $29.10 and its 200-day moving average price is $34.11. The company has a market capitalization of $1.26 billion, a price-to-earnings ratio of 58.44, a price-to-earnings-growth ratio of 7.84 and a beta of 0.76. The company has a debt-to-equity ratio of 0.13, a quick ratio of 1.23 and a current ratio of 1.38.

Omnicell (NASDAQ:OMCL - Get Free Report) last posted its quarterly earnings results on Tuesday, May 6th. The company reported $0.26 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.16 by $0.10. Omnicell had a net margin of 1.87% and a return on equity of 4.60%. The company had revenue of $269.67 million during the quarter, compared to the consensus estimate of $260.18 million. During the same period last year, the firm earned $0.03 EPS. The company's revenue for the quarter was up 9.5% on a year-over-year basis. On average, equities analysts forecast that Omnicell, Inc. will post 1.09 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of analysts have weighed in on OMCL shares. Wall Street Zen upgraded Omnicell from a "buy" rating to a "strong-buy" rating in a research note on Saturday, July 12th. Wells Fargo & Company restated an "overweight" rating and issued a $37.00 price target (up from $35.00) on shares of Omnicell in a research note on Friday, May 23rd. Piper Sandler restated an "overweight" rating on shares of Omnicell in a research note on Friday, May 23rd. Bank of America raised their price target on Omnicell from $30.00 to $34.00 and gave the company a "neutral" rating in a research note on Friday, May 23rd. Finally, Benchmark cut their price target on Omnicell from $62.00 to $40.00 and set a "buy" rating on the stock in a research note on Wednesday, May 7th. Three investment analysts have rated the stock with a hold rating, four have issued a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat.com, Omnicell currently has a consensus rating of "Moderate Buy" and an average price target of $44.83.

Omnicell Company Profile

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.